MedTrace Logo

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

NCT00056173 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2008-01-07

No results posted yet for this study

Summary

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Conditions

  • Carcinoma, Renal Cell
  • Metastases, Neoplasm

Interventions

DRUG

GTI-2040

Sponsors & Collaborators

  • Wake Forest University

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Aptose Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056173 on ClinicalTrials.gov